Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventative therapy in primary biliary cirrhosis.

Annarosa Floreani1

  • 1Department of Surgical and Gastroenterological Sciences, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy. annarosa.floreani@unipd.it

Clinics in Liver Disease
|November 5, 2003
PubMed
Summary

Preventative therapies for primary biliary cholangitis (PBC) lack evidence. Future gene therapies show promise, but current management focuses on preventing complications like osteopenia and portal hypertension.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Life (Basel, Switzerland)·2026
Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Expert opinion on investigational drugs·2025
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025
Same author

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Expert review of gastroenterology & hepatology·2025
Same author

Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world.

JHEP reports : innovation in hepatology·2025

Area of Science:

  • Hepatology
  • Immunology
  • Preventative Medicine

Background:

  • The exact cause of primary biliary cholangitis (PBC) remains unknown, leading to empirical treatment strategies.
  • Currently, no evidence-based preventative therapies for PBC have been published.
  • Two patient groups could potentially benefit from preventative therapy: AMA-positive individuals with normal liver enzymes and transplanted patients without disease recurrence.

Purpose of the Study:

  • To explore the potential for preventative therapies in primary biliary cholangitis.
  • To address the challenges in selecting appropriate treatments for at-risk PBC patient groups.
  • To discuss future directions in PBC prevention, including gene therapy.

Main Methods:

  • Review of current understanding of PBC etiology and treatment.

Related Experiment Videos

  • Analysis of potential candidates for preventative therapy.
  • Discussion of existing and future therapeutic options, including ursodeoxycholic acid (UDCA) and gene therapy.

    • Main Results:

    • The efficacy of UDCA, a common treatment, is questioned regarding survival benefits.
    • PBC is theorized to be an autoimmune disease with genetic predisposition, potentially triggered by environmental factors.
    • Current practical preventative management focuses on complications such as osteopenia and portal hypertension.

    Conclusions:

    • Preventative therapy for PBC is currently not supported by robust evidence.
    • Gene therapy represents a promising future avenue for PBC prevention.
    • Immediate preventative strategies should target known complications of PBC.